Abstract
D&MDs Angiogenesis Modulators: Strategies for Drug Discovery Report provides an up-to-date
assessment of current directions and prospects in the angiogenesis modulators field. After three
decades of research in this field, human trials of angiomodulatory compounds are at last beginning
to yield commercial products with proven efficacy. Many diverse drugs targeting angiogenesis are in
clinical development. This report offers a comprehensive review of targets for angiogenesis
modulation, identifies the most promising approaches, and assesses the prospects for angiogenesis
modulators in different therapeutic areas. The Report highlights commercial opportunities for
angiogenesis inhibitors such as new therapeutic modalities in cancer, ophthalmic diseases, vascular
skin diseases, and chronic inflammatory diseases. It also assesses current and potential
applications of angiogenesis stimulators in tissue revascularization.
TABLE OF CONTENTS
Chapter 1: Executive Summary
Chapter 2: Introduction To Angiogenesis
- Overview of Angiogenesis
- The Process of Angiogenesis
- Molecules Involved in Angiogenesis
- Growth Factors and Other Angiogenic Proteins
- Receptor Tyrosine Kinases
- Proteases
- Cell Adhesion Molecules
- Endogenous Antiangiogenic Proteins
- Role of Angiogenesis in Disease
- Approaches to Angiogenesis Modulation
- Types of Drugs under Development
- Small-Molecule Drugs
- Biopharmaceuticals
- Assays for Angiogenesis
Chapter 3: Angiogenesis In Cancer
- Overview of Cancer
- Cancer Therapy
- Molecular Targeted Therapies
- Angiogenesis in Cancer
- Angiostatic versus Angiolytic Therapies
- Targets for Angiostatic Therapies
- Growth Factors and Their Receptors
- VEGF-A
- VEGFR Family
- EGFR Family
- Small-Molecule Drugs
- Monoclonal Antibody Drugs
- Other Growth Factors/Receptors
- Tie2 Receptor
- IGF1R
- FGF-2
- VEGF-C, VEGF-D/VEGFR-3
- PDGF(R)
- Multi-Target Strategies
- Applications in Hematologic Malignancies
- ECM-Degrading Enzymes
- Matrix Metalloproteases
- Heparanase
- Proteases (other than MMPs)
- ADAMs Family
- uPA
- Other Proteases
- Cell Adhesion Receptors
- Alpha(v) Integrins
- Other Cell Adhesion Receptors
- Agents Based on Human Antiangiogenic Factors
- Endogenous Antiangiogenic Factors
- Antiangiogenic Gene Therapy
- Agents of Non-Human Origin
- Miscellaneous Agents
- Thalidomide-Related Drugs
- Other Drugs
- Angiolytic Vascular Targeting Agents
- Small-Molecule VTAs
- Tubulin-Binding Agents
- Other Small-Molecule Agents
- Ligand-based and Other VTAs
- Exploiting Angiogenesis for Drug Delivery
Chapter 4: Angiogenesis In Cardiology
- Overview of Cardiovascular Disease
- Coronary Artery Disease
- Myocardial Infarction
- Peripheral Vascular Disease
- Congestive Heart Failure
- Angiogenesis in Ischemia
- Physiological Responses to Ischemia
- Stimulation of Angiogenesis in Ischemia
- Transmyocardial Revascularization
- Therapeutic Angiogenesis
- Cell Therapy
- Challenge of Pathologic Angiogenesis
- Atherogenesis and Atheroscleropathy
- Percutaneous Coronary Interventions
- Approaches to Restenosis Prevention
- Angiogenic Products in Commercial Development
- Protein and Small Molecule Therapies
- Gene Therapies
- Cell Therapies
- Stem and Progenitor Cell Therapies
Chapter 5: Angiogenesis In Ophthalmology
- Eye Diseases Involving Neovascularization
- Age-related Macular Degeneration
- Diabetic Retinopathy
- Other Disorders
- Angiolytic Photodynamic Therapy
- Angiogenesis-targeting Drugs
- Angiostatic Drugs
- Targeting VEGF/VEGFR
- Miscellaneous Targets
- Vascular Targeting Agents
Chapter 6: Other Applications Of Angiogenic Modulation
- Introduction
- Skin Diseases
- Chronic Wounds
- Vascular Lesions
- Psoriasis
- Rosacea
- Other Vascular Lesions
- Chronic In.ammatory Diseases
- Rheumatoid Arthritis
- Periodontitis
- In.ammatory Bowel Disease
- In.ammatory Lung Diseases
- Complex Regional Pain Syndrome
- Fibrodysplasia Ossi.cans Progressiva
- Transplant Rejection
- Orthodontic Applications
- Spinal Cord Injuries
- Other Potential Applications
- Endometriosis
- Obesity
- Erectile Dysfunction
- Benign Tumors
Chapter 7: Company Profiles
- Introduction
- Abbott Laboratories
- AEterna Zentaris Inc
- Alcon Laboratories Inc
- Amgen Inc
- Angiotech Pharmaceuticals Inc
- Antisoma Plc
- AstraZeneca Plc
- Bayer AG
- Boston Scienti.c Corporation
- Celgene Corporation
- Collagenex Pharmaceuticals Inc
- Collateral Therapeutics Inc
- Corautus Genetics Inc
- EntreMed Inc
- EyeTech Pharmaceuticals Inc
- Genaera Corporation
- Genentech Inc
- Genzyme Corporation
- GlaxoSmithKline Plc
- Human Genome Sciences
- ImClone Systems Inc
- Merck KGaA
- Merck & Co Inc
- Novartis Pharma AG
- OSI Pharmaceuticals Inc
- OXiGENE Inc.
- P.zer Inc
- Regeneron Pharmaceuticals Inc.
- Sirna Therapeutics Inc
Chapter 8: The Angiogenesis Modulation Market To 2009
- Introduction
- Cancer
- Overview
- Established Cancer Therapies
- The Anti-Cancer Drug Market
- Cardiology
- Overview
- Coronary Artery Disease
- Myocardial Infarction
- Congestive Heart Failure
- Established Treatments
- Cardiology drug market
- Ophthalmology
- Overview
- Age-related Macular Degeneration
- Diabetic Retinopathy
- Other Eye Disorders
- Ophthalmology Drug Market
- Dermatology
- Overview
- Psoriasis
- Benign Vascular Lesions
- Impaired Wound Healing
- Dermatology Drug Market
- Other Indications
- Market Forecasts
Chapter 9: Conclusions, Trends, and Opportunities
- Gap Narrows between Experimental and Clinical Data
- VEGF Inhibitors Lead the Way
- Cancer: Opportunities Expand
- Accelerating Approvals
- Learning from Clinical Trials
- Optimizing Therapies
- Towards Pharmacogenomic Testing
- Towards Angiogenic Pro.ling
- Taking Advantage of Vascular Targeting
- Future Horizons䊼ancer Prevention?
- AMD: Breakthrough Treatments Emerge
- Cardiology: Interest Peaks Despite Slow Progress
- Other Diseases: Largely Unexplored Opportunities
- Exploiting Unexpected Angiomodulatory Effects
TABLE OF EXHIBITS
- Exhibit 2.1 Partial List of Endogenous Angiogenic Factors
- Exhibit 2.2 Partial List of Endogenous Antiangiogenic Factors
- Exhibit 3.1 Cancer: Inhibitors of Growth Factors/receptors Listed by Drug Target
- Exhibit 3.2 Cancer: Inhibitors of ECM-degrading Enzymes, List by Drug Target
- Exhibit 3.3 Cancer: Inhibitors of Proteases (other than MMPs), Listed by Drug Target
- Exhibit 3.4 Cancer: Inhibitors of Cell Adhesion Receptors
- Exhibit 3.5 Cancer: Agents Based on Human Antiangiogenic Factors
- Exhibit 3.6 Cancer: Antiangiogenic Substances of Non-human Origin
- Exhibit 3.7 Cancer: Miscellaneous Agents with Antiangiogenic Properties
- Exhibit 3.8 Cancer: Vascular Targeting Agents
- Exhibit 4.1 Cardiovascular Diseases: Angiogenic Therapies
- Exhibit 5.1 Vascular Eye Diseases: Antiangiogenic Therapies
- Exhibit 6.1 Dermatology: Angiogenic and Antiangiogenic Therapies
- Exhibit 6.2 Miscellaneous Indications: Antiangiogenic Therapies
- Exhibit 7.1 The 25 Most Active Organizations in Angiogenesis-related US Patenting, 1995 - 2004 (Granted Patents)
- Exhibit 7.2 The 25 Most Active Organizations in Angiogenesis-related US Patenting, 2002 - 2004 (Published Applications)
- Exhibit 7.3 The 25 Most Frequently Cited Angiogenesis-related US Patents, 1995 - 2004
- Exhibit 8.1 World Prevalence Of Angiogenesis-Related Diseases
- Exhibit 8.2 World Market For Angiogenesis-Related Diseases
- Exhibit 8.3 World Pharma Market In 2004 and 2009
- Exhibit 8.4 Angiogenesis-Related Markets By Indication
- Exhibit 8.5 World Angiogenesis-Related Market In 2004 And 2009
|
